A citation-based method for searching scientific literature

H Oda, A Mori, P Lee, K Saeki, K Ishioka, T Arai, T Sako. Res Vet Sci 2013
Times Cited: 4







List of co-cited articles
8 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Intestinal factors in the control of insulin secretion.
N McIntyre, C D Holdsworth, D S Turner. J Clin Endocrinol Metab 1965
408
50

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
61
50

Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs.
Lindsay B Harrison, Pablo F Mora, Gregory O Clark, Ildiko Lingvay. J Investig Med 2013
35
50

Detemir insulin for the treatment of diabetes mellitus in dogs.
Federico Fracassi, Sara Corradini, Michaela Hafner, Felicitas S Boretti, Nadia S Sieber-Ruckstuhl, Claudia E Reusch. J Am Vet Med Assoc 2015
8
50

What's in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters.
C Gilor, S J M Niessen, E Furrow, S P DiBartola. J Vet Intern Med 2016
41
50

Glargine insulin for treatment of naturally occurring diabetes mellitus in dogs.
Rebecka S Hess, Kenneth J Drobatz. J Am Vet Med Assoc 2013
13
50

Epidemiology of Diabetes Mellitus among 193,435 Cats Attending Primary-Care Veterinary Practices in England.
D G O'Neill, R Gostelow, C Orme, D B Church, S J M Niessen, K Verheyen, D C Brodbelt. J Vet Intern Med 2016
23
50

Efficacy of protamine zinc recombinant human insulin for controlling hyperglycemia in dogs with diabetes mellitus.
A Della Maggiore, R W Nelson, J Dennis, E Johnson, P H Kass. J Vet Intern Med 2012
15
50




Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes.
W C Lee, M Dekoven, J Bouchard, M Massoudi, J Langer. Diabetes Obes Metab 2014
26
25


Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
25

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Gary A Herman, Cathy Stevens, Kristien Van Dyck, Arthur Bergman, Bingming Yi, Marina De Smet, Karen Snyder, Deborah Hilliard, Michael Tanen, Wesley Tanaka,[...]. Clin Pharmacol Ther 2005
357
25


Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.
Kenji Nonaka, Taro Kakikawa, Asako Sato, Kotoba Okuyama, Go Fujimoto, Naoki Kato, Hideyo Suzuki, Yukio Hirayama, Tuli Ahmed, Michael J Davies,[...]. Diabetes Res Clin Pract 2008
156
25



Canine diabetes mellitus: can old dogs teach us new tricks?
B Catchpole, J M Ristic, L M Fleeman, L J Davison. Diabetologia 2005
73
25


Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
89
25

Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
Y Iwamoto, N Tajima, T Kadowaki, K Nonaka, T Taniguchi, M Nishii, J C Arjona Ferreira, J M Amatruda. Diabetes Obes Metab 2010
83
25

The role of gut hormones in glucose homeostasis.
Daniel J Drucker. J Clin Invest 2007
403
25

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Arthur J Bergman, Catherine Stevens, YanYan Zhou, Bingming Yi, Martine Laethem, Marina De Smet, Karen Snyder, Deborah Hilliard, Wesley Tanaka, Wei Zeng,[...]. Clin Ther 2006
207
25

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.
M A Nauck, E Homberger, E G Siegel, R C Allen, R P Eaton, R Ebert, W Creutzfeldt. J Clin Endocrinol Metab 1986
566
25

Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
Ottavio Giampietro, Chiara Giampietro, Luca Della Bartola, Maria Chiara Masoni, Elena Matteucci. Drug Des Devel Ther 2013
22
25

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Gary A Herman, Arthur Bergman, Catherine Stevens, Paul Kotey, Bingming Yi, Peng Zhao, Bruno Dietrich, George Golor, Andreas Schrodter, Bart Keymeulen,[...]. J Clin Endocrinol Metab 2006
381
25

Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes.
Chee W Chia, Olga D Carlson, Wook Kim, Yu-Kyong Shin, Cornelia P Charles, Hee Seung Kim, Denise L Melvin, Josephine M Egan. Diabetes 2009
105
25

Novel GLP-1 receptor agonists for diabetes.
Alan J Garber. Expert Opin Investig Drugs 2012
48
25

Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
68
25

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Dooseop Kim, Liping Wang, Maria Beconi, George J Eiermann, Michael H Fisher, Huaibing He, Gerard J Hickey, Jennifer E Kowalchick, Barbara Leiting, Kathryn Lyons,[...]. J Med Chem 2005
561
25

Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
Maria G Beconi, James R Reed, Yohannes Teffera, Yuan-Qing Xia, Christopher J Kochansky, David Q Liu, Shiyao Xu, Charles S Elmore, Suzanne Ciccotto, Donald F Hora,[...]. Drug Metab Dispos 2007
36
25

Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
Jian Luo, Kathy Nguyen, Michael Chen, Than Tran, Jianqiang Hao, Bole Tian, Ingrid C Rulifson, Ying Zhang, Lei Tian, Yu Zhang,[...]. Metabolism 2013
12
25

Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action.
Viorica Ionut, Idit F Liberty, Katrin Hucking, Maya Lottati, Darko Stefanovski, Dan Zheng, Richard N Bergman. Am J Physiol Endocrinol Metab 2006
29
25

Stimulation of insulin secretion and improvement of glucose tolerance in rat and dog by the P2y-purinoceptor agonist, adenosine-5'-O-(2-thiodiphosphate).
D Hillaire-Buys, G Bertrand, J Chapal, R Puech, G Ribes, M M Loubatières-Mariani. Br J Pharmacol 1993
31
25

Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.
T Vilsbøll, H Agersø, T Krarup, J J Holst. J Clin Endocrinol Metab 2003
303
25





Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies.
Shin Tsunekawa, Naoki Yamamoto, Katsura Tsukamoto, Yuji Itoh, Yukiko Kaneko, Toshihide Kimura, Yoh Ariyoshi, Yoshitaka Miura, Yutaka Oiso, Ichiro Niki. J Endocrinol 2007
76
25

DPP-4 inhibitors.
Bo Ahrén. Best Pract Res Clin Endocrinol Metab 2007
117
25

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.
Yazhou Li, Tanya Hansotia, Bernardo Yusta, Frederic Ris, Philippe A Halban, Daniel J Drucker. J Biol Chem 2003
464
25

Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.
Norihiko Ogawa, James F List, Joel F Habener, Takashi Maki. Diabetes 2004
127
25


Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes.
J Zhang, Y Tokui, K Yamagata, J Kozawa, K Sayama, H Iwahashi, K Okita, M Miuchi, H Konya, T Hamaguchi,[...]. Diabetologia 2007
55
25

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
T Vilsbøll, T Krarup, J Sonne, S Madsbad, A Vølund, A G Juul, J J Holst. J Clin Endocrinol Metab 2003
363
25

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.
D A Stoffers, T J Kieffer, M A Hussain, D J Drucker, S Bonner-Weir, J F Habener, J M Egan. Diabetes 2000
453
25



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.